Presentation Transcript
No time to wait: taking legal action to increase access to HIV medicines: No time to wait: taking legal action to increase access to HIV medicines Jonathan Berger
Senior Researcher
AIDS Law Project
SOUTH AFRICA Bridging Session
Access to Treatment: People Before Trade
Wednesday, August 16th 2006
XVI International AIDS Conference
_________________________________________________________
Overview of presentation: Overview of presentation _________________________________________________________ South African context
Access concerns
Political context
Constitutional framework
Case studies
Hazel Tau vs. GSK and Boehringer Ingelheim
BMS’s Amphotericin B (Fungizone®)
Concluding thoughts
South African context: South African context _________________________________________________________ Access concerns
Excessive pricing
Sustainability of supply
Political context
Government inaction
Civil society leadership
Constitutional framework
Socio-economic rights protections
Positive state obligations
Interpretation of all legislation
Case studies: Case studies _________________________________________________________ Hazel Tau vs. GSK and Boehringer Ingelheim
Focus on three essential ARVs: AZT, 3TC and NVP
Patent-protected
No generic competition
Excessive private sector prices
BMS’s Amphotericin B (Fungizone®)
Gold standard for cryptococcal meningitis
Off-patent
No generic competition
Excessive public and private sector prices
Tau v GSK and BI: Tau v GSK and BI _________________________________________________________ GSK and BI alleged to have “engaged in excessive pricing of ARVs to the detriment of consumers”
Conduct was alleged to be –
Directly responsible
For the premature, predictable and avoidable deaths
Of people living with HIV/AIDS
In contravention of section 8(a) of the Competition Act, 89 of 1998
As interpreted in light of the Constitution
What had to be proven?: What had to be proven? _________________________________________________________ Charging a price for a good or service which –
Bears no reasonable relation to the economic value of that good or service; and
Is higher than this value
What makes up the economic value?
Manufacturing costs
R&D costs (where applicable)
Licensing costs (where applicable)
Reasonable profits
???
Reasonable relation = balancing of rights
Resolution by settlement: Resolution by settlement _________________________________________________________ Matter settled in December 2003
Avoided Competition Tribunal public hearing
Complex legal issues remain unresolved
Implementation of settlement
Excessive pricing complaint, but licensing solution
Reasonable terms and conditions
Public and private sectors
Imports and/or local production of products (including FDCs)
Exports of locally produced ARVs to sub-Saharan Africa
5% royalty maximum (including for FDCs)
Price reductions: Price reductions _________________________________________________________
Amphotericin B: Amphotericin B _________________________________________________________ Need for access
Cryptococcal meningitis has 25 – 40% mortality rate in people living with HIV/AIDS
Limited use in public sector primarily as result of price
Private sector price even higher
Legal action
Threat of excessive pricing action
Request for justification of pricing policy
Matter settled after series of letters
Private/public divide overcome
Price reduction of between 80% and 85%
Concluding thoughts: Concluding thoughts _________________________________________________________ Civil society took the lead
No government-issued licences under Patents Act
Not even threats of issuing licences
State willing to let civil society do its “dirty work”
Chilling effect of TRIPs+ compulsory licensing provisions
Failure to implement Doha Declaration
No licences issued by courts on any patented products
No applications for licences by generic manufacturers of ARVs
Need for regulatory reform
Express licensing remedy for excessive pricing
Implement the Doha Declaration
Slide11: Go to www.AIDStruth.org for accurate information on HIV/AIDS and to learn about how AIDS denialists twist the truth and peddle lies. AIDS
DENIALISM